Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OP
Optimi Health Corp. Common Shares
OPTH
Mkt Cap
$19.8M
Volume
19.58K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OP
OPTH
OP
Optimi Health Corp. Common Shares
OPTH
News
·
Optimi Health to Present at the ThinkEquity Conference
Mkt Cap
$18.3M
Volume
19.58K
Next Earnings
November 13th
Chart
Earnings
News
About
Insider
Filings
Optimi Health to Present at the ThinkEquity Conference
Optimi Health Corp., a commercial-stage pharmaceutical manufacturer of psychedelic drug products, announced its participation in the ThinkEquity Conference on October 15, 2026, in New York City. Management will present a corporate overview and meet with investors. The company is a Health Canada-licensed manufacturer producing GMP-grade MDMA and psilocybin products for mental health therapies.
GlobeNewswire Inc. · Oct 7, 2026
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health completed its third commercial shipment of 5mg psilocybin capsules to Australia, exporting 1,000 capsules for treatment-resistant depression patients. The company reports no serious adverse events since the September 2025 launch and notes expanding reimbursement coverage from both private and public insurers in Australia.
GlobeNewswire Inc. · Jun 29, 2026
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.
Benzinga · Jun 18, 2026
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health Corp. announced the completion of two standardized microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations. The products offer consistent, validated doses derived from naturally sourced psilocybin, extending Optimi's existing 5mg formulation currently prescribed for treatment-resistant depression in Australia. All production is conducted in-house at Optimi's GMP-compliant facility in British Columbia, Canada.
Benzinga · Jun 16, 2026
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health has completed a GMP production run of its 5mg psilocybin finished drug product for commercial use in Australia to treat treatment-resistant depression. The company manufactures the entire product in-house at its Health Canada-licensed facility, from biomass cultivation through final packaging. Additional product from the run will support clinical trials in the United States and Europe.
Benzinga · Jun 2, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
OP
OPTH
Optimi Health Corp. Common Shares
Buy
Sell
Market
Limit
Soon
OPTH
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any OPTH yet.
Related Tickers
Earnings